Allogenic stem cell transplant in patients over the age of 70, including octogenarians, with hematologic malignancies: A single institution experience.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e18538-e18538
Author(s):  
Robert E. Gaudet ◽  
Jan Cerny ◽  
Muthalagu Ramanathan ◽  
Glen Raffel ◽  
Zheng Zhou ◽  
...  
Keyword(s):  
Stem Cell ◽  
Treatment Modality ◽  
Stem Cell Transplant ◽  
Medical Center ◽  
Hematologic Malignancies ◽  
Cell Transplant ◽  
Single Institution ◽  
Allogenic Stem Cell Transplant ◽  
Unrelated Donors ◽  
Grade Ii

e18538 Background: Patient age is an important factor when considering allogenic stem cell transplant (aSCT) as a treatment modality for hematologic malignancies. Previous series exploring older age and outcome in aSCT have generally not included fit, older adults beyond the age of 80: a group typically considered ineligible for aSCT. This report describes our single-institution experience with aSCT in patients age 70 and older, including octogenarians, from March 2010 through April 2016. Methods: Retrospective analysis was performed on all patients older than 70 years undergoing aSCT at UMass Memorial Medical Center (UMMMC) between March 2010 and April 2016. The study was approved by the UMMMC IRB. Results: 32 patients were identified: 19 men and 13 women. 1 patient underwent a second aSCT in the study period. Median age at time of aSCT was 73 years (range 70-83). 4 patients were age >80. Diseases treated were AML (19 pts.), MDS (12 pts.), and CLL (1 pt.). 24 transplants were performed with unrelated donors: 17 with 10/10 match, 3 with 11/12 match, 3 with 10/12 match, and 1 with 9/12 match. 9 were performed with umbilical cord blood units. Grade II-IV acute GVHD developed in 9 patients (27%). Day 100 survival by age following the transplant were 11/18 (61%) for patients aged 70-75, 6/10 (60%) for patients aged 75-80 and 4/4 (100%) for patients aged 80-85. Conclusions: Allogenic Stem Cell Transplant is a viable treatment modality in highly-selected elderly patients with hematologic malignancies. Further studies are warranted in a prospective fashion. [Table: see text]

scholarly journals Immune Therapies for Hematologic Malignancies

Cancers ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 295
Author(s):  
Matthew J. Olnes
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell ◽  
Hematopoietic Stem Cell Transplant ◽  
Stem Cell Transplant ◽  
Hematologic Malignancies ◽  
Cell Transplant ◽  
Hematopoietic Stem ◽  
Immune Therapies

The era of immunotherapy for hematologic malignancies began with the first allogeneic hematopoietic stem cell transplant (HSCT) study published by E [...]

Results of an Autologous Noncryopreserved, Unmanipulated Peripheral Blood Hematopoietic Stem Cell Transplant Program: A Single-Institution, 10-Year Experience

2003 ◽  
Vol 110 (4) ◽  
pp. 179-183 ◽  
Author(s):  
Guillermo J. Ruiz-Argüelles ◽  
David Gómez-Rangel ◽  
Guillermo J. Ruiz-Delgado ◽  
Alejandro Ruiz-Argüelles ◽  
Beatriz Pérez-Romano ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell ◽  
Peripheral Blood ◽  
Hematopoietic Stem Cell Transplant ◽  
Stem Cell Transplant ◽  
Cell Transplant ◽  
Single Institution ◽  
Hematopoietic Stem ◽  
Transplant Program

Characteristics and outcomes of progressive multifocal leukoencephalopathy in hematologic malignancies and stem cell transplant – a case series

2018 ◽  
Vol 60 (2) ◽  
pp. 395-401 ◽  
Author(s):  
Diego Adrianzen Herrera ◽  
Sabarish Ayyappan ◽  
Sakshi Jasra ◽  
Noah Kornblum ◽  
Olga Derman ◽  
...  
Keyword(s):  
Stem Cell ◽  
Progressive Multifocal Leukoencephalopathy ◽  
Stem Cell Transplant ◽  
Case Series ◽  
Hematologic Malignancies ◽  
Cell Transplant

Efficacy of a conversion from filgrastim to filgrastim-sndz in stem cell transplant patients undergoing mobilization

2020 ◽  
pp. 107815522094158
Author(s):  
Lauren D Curry ◽  
Brandi Anders ◽  
Emily V Dressler ◽  
LeAnne Kennedy
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplant ◽  
Medical Center ◽  
Hematopoietic Cells ◽  
The United States ◽  
Similar Efficacy ◽  
Median Number ◽  
Autologous Stem Cell Transplant ◽  
Cell Transplant ◽  
Biosimilar Product

During autologous stem cell transplant, granulocyte colony-stimulating factors (G-CSF) serve the integral role of mobilizing hematopoietic cells into the peripheral blood for subsequent collection by leukapheresis. Filgrastim (Neupogen®) is a G-CSF and affects hematopoietic cells by stimulating growth and differentiation of neutrophils. Filgrastim-sndz (Zarxio®), a biosimilar of filgrastim, received landmark approval as the first biosimilar product approved by the FDA in the United States. As a result of the recent FDA approval, our medical center made the conversion in August 2016 from using filgrastim to filgrastim-sndz to provide patients the same benefits of the filgrastim injection at a reduced cost. This retrospective, observational cohort study evaluated the comparative efficacy of the filgrastim-sndz biosimilar in 147 patients who underwent mobilization prior to stem cell transplant with filgrastim between 1 August 2015 and 31 July 2016 or filgrastim-sndz between 1 September 2016 and 30 November 2017. The mean number of CD34 cells collected during apheresis was 7.38 × 106 in the filgrastim group and 8.86 × 106 in the filgrastim-sndz group. Filgrastim-sndz was significantly non-inferior, as the difference between filgrastim and filgrastim-sndz was −1.48 × 106 with an upper 95% confidence bound equal to −0.24 × 106 that did not include the non-inferiority margin of 1 × 106 ( p = 0.0006). The median number of days of apheresis was 2 in both groups ( p= 0.3273). In conclusion, the biosimilar product was non-inferior for mobilization and the conversion from filgrastim to filgrastim-sndz afforded patients similar efficacy for mobilization in stem cell transplant at a reduced cost.

Sign in / Sign up

Export Citation Format

Share Document